Search research articles
Contact Us
Filters
Showing results (171-180 of 284) with videos related to
Page
of 29
Sort By:
BMC Cancer
|
July 24, 2020
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
Carlotta Antoniotti, Beatrice Borelli, Daniele Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2020
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest
Roberto Moretto, Daniele Rossini, Gemma Zucchelli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2019
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3
Alberto Puccini, Fotios Loupakis, Sebastian Stintzing, et al.
The Oncologist
|
April 14, 2026
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer
Vincenzo Nasca, Margherita Ambrosini, Julien Taieb, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 12, 2019
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial
Gianluca Masi, Caterina Vivaldi, Lorenzo Fornaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, et al.
ESMO Open
|
April 10, 2019
Benefit from anti-EGFRs in <i>RAS</i> and <i>BRAF</i> wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
Chiara Cremolini, Matteo Benelli, Elisa Fontana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2016
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest
Chiara Cremolini, Mariaelena Casagrande, Fotios Loupakis, et al.
Frontiers in Oncology
|
February 26, 2024
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
Marco Maria Germani, Guglielmo Vetere, Mirella Giordano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2016
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
Filippo Pietrantonio, Claudio Vernieri, Giulia Siravegna, et al.
Page
of 29
Search research articles
Search
Showing results (171-180 of 284) with videos related to
Sort By:
Page
of 29
BMC Cancer
|
July 24, 2020
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
Carlotta Antoniotti, Beatrice Borelli, Daniele Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2020
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest
Roberto Moretto, Daniele Rossini, Gemma Zucchelli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2019
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3
Alberto Puccini, Fotios Loupakis, Sebastian Stintzing, et al.
The Oncologist
|
April 14, 2026
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer
Vincenzo Nasca, Margherita Ambrosini, Julien Taieb, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 12, 2019
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial
Gianluca Masi, Caterina Vivaldi, Lorenzo Fornaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, et al.
ESMO Open
|
April 10, 2019
Benefit from anti-EGFRs in <i>RAS</i> and <i>BRAF</i> wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
Chiara Cremolini, Matteo Benelli, Elisa Fontana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2016
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest
Chiara Cremolini, Mariaelena Casagrande, Fotios Loupakis, et al.
Frontiers in Oncology
|
February 26, 2024
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
Marco Maria Germani, Guglielmo Vetere, Mirella Giordano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2016
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
Filippo Pietrantonio, Claudio Vernieri, Giulia Siravegna, et al.
Page
of 29